Novel therapy against human cancers using intra-nuclear transportable humanized monoclonal antibody against CD26.
Novel therapy against human cancers using intra-nuclear transportable humanized monoclonal antibody against CD26.
批准号:
16H04714
负责人:
YAMADA TAKETO
金额:
$10.82万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2016
资助国家:
日本
项目状态:
已结题
起止时间:
2016-04-01 至 2019-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
IL-26 facilitates angiogenesis and skin inammation via inducing FGF2 production in a murine model of imiquimod-induced psoriasis.
在咪喹莫特诱导的牛皮癣小鼠模型中,IL-26 通过诱导 FGF2 产生来促进血管生成和皮肤炎症。
DOI:
--
发表时间:
2017
期刊:
影响因子:
--
作者:
[Itoh T, Hatano R, Otsuka H, Iwao N, Iwata S, Yamada T , Morimoto C.]
通讯作者:
Morimoto C.
Humanized anti-CD26 monoclonal antibody, YS110, has anti-myeloma efficacy for the treatment of high-risk multiple myeloma.
人源化抗CD26单克隆抗体YS110具有抗骨髓瘤功效,可用于治疗高危多发性骨髓瘤。
DOI:
--
发表时间:
2017
期刊:
影响因子:
--
作者:
[Nishida H, Hayashi M, Morimoto C, Sakamoto M, Yamada T.]
通讯作者:
Yamada T.
PEG(E)-TC11, a novel polyethylene glycol-linked phthalimide derivative, inhibited high-risk MM cell growth in vivo and in vitro via cell cycle G2/M arrest in a CRBN-independent manner.
PEG(E)-TC11 是一种新型聚乙二醇连接的邻苯二甲酰亚胺衍生物,可通过细胞周期 G2/M 停滞以不依赖 CRBN 的方式抑制体内和体外高危 MM 细胞的生长。
DOI:
--
发表时间:
2017
期刊:
影响因子:
--
作者:
[Aida S, Ichikawa D, Iida K, Hozumi M, Nakamura M, Uozaki R, Hashimoto N, Okayama M, Yonemura Y, Tabata N, Yamada T, Matsushita M, Sugai T, Yanagawa H, Hattori Y]
通讯作者:
Hattori Y
Humanized anti-CD26 antibody conjugated with RNA polymerase II inhibitor Triptolide suppresses tumor
人源化抗 CD26 抗体与 RNA 聚合酶 II 抑制剂雷公藤甲素缀合可抑制肿瘤
DOI:
--
发表时间:
2016
期刊:
影响因子:
--
作者:
[林 睦, 間所裕子, 山田幸司, 西田浩子, 坂元亨宇, 森本幾夫, 山田健人]
通讯作者:
山田健人
A novel phenylphthalimide derivative, pegylated TC11, improves pharmacokinetic properties and induces apoptosis of high-risk myeloma cells via G2/M cell-cycle arrest.
聚乙二醇化 TC11 是一种新型苯基邻苯二甲酰亚胺衍生物,可改善药代动力学特性,并通过 G2/M 细胞周期阻滞诱导高危骨髓瘤细胞凋亡。
DOI:
10.1016/j.bbrc.2017.08.159
发表时间:
2017
期刊:
Biochem. Biophysic. Res. Commun.
影响因子:
--
作者:
[Aida S, Hozumi M, Ichikawa D, Iida K, Yonemura Y, Tabata N, Yamada T, Matsushita M, Sugai T, Yanagawa H, Hattori Y]
通讯作者:
Hattori Y
共 19 条
Novel anti-cancer therapy against super-enhancer using humanized monoclonal antibody with transportation activity into nucleus
-
批准号:19H03519
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.07万
-
财政年份:2019
-
负责人:YAMADA TAKETO
-
依托单位:
Human natural helper cells and its involvement in diseases
-
批准号:23390086
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.65万
-
财政年份:2011
-
负责人:YAMADA TAKETO
-
依托单位:
海外基金